Cyril Amarchand Mangaldas advised the promoters of Suven Pharmaceuticals Limited (Suven Pharmaceuticals) in relation to the acquisition of Suven Pharmaceuticals by global private equity firm Advent, for an aggregate amount of INR 9,500 crore (approx.) through a share purchase agreement for c. 51% followed by an open offer for 26%. The General Corporate and Competition Law Practices of Cyril […]
The post Cyril Amarchand Mangaldas advises sellers on INR 9,500 crore acquisition by Advent appeared first on Legal Desire.